--- title: "Cadrenal Therapeutics (CVKD) news: offering" url: "https://aibio.space/companies/cadrenal-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "CVKD offering news: Cadrenal Therapeutics raises $3.0 million in private placement priced at-the-market. Cadrenal Therapeutics, Inc." --- CVKD Cadrenal Therapeutics, Inc. NASDAQ · United States # Cadrenal Therapeutics (CVKD) news CVKD offering news Financings · 2026-07-01 ## [Cadrenal Therapeutics raises $3.0 million in private placement priced at-the-market](https://aibio.space/news/cadrenal-therapeutics-raises-3-0-million-private-placement-priced/) Cadrenal (Nasdaq: CVKD) received gross proceeds of approximately $3.0 million from one institutional investor. Warrants could add about $5.8 million if exercised in full for cash, the company says. ## Latest Cadrenal Therapeutics news 1. 2025-12-16 Financings [Cadrenal Therapeutics agrees to $2.2 million registered direct offering with warrants](https://aibio.space/news/cadrenal-therapeutics-agrees-2-2-million-registered-direct-offering/) Cadrenal will sell 207,374 shares at $10.85 plus unregistered warrants for up to 414,748 shares at $10.60, for expected gross proceeds of about $2.2 million. H.C. Wainwright & Co., LLC is exclusive placement agent. 2. 2025-04-17 Financings [Cadrenal Therapeutics files to sell up to $2,169,272 more stock through ATM program](https://aibio.space/news/cadrenal-therapeutics-files-sell-up-2-169-272-more-stock-through-atm/) Cadrenal can sell up to $2,169,272 of common stock through H.C. Wainwright & Co., LLC, after it has already sold $7,655,240 under the same agreement. The sales are capped by an SEC rule that applies because its public float is under $75 million. ## Cadrenal Therapeutics at a glance - **Ticker**: CVKD - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $2.4 million ### Related companies - [Janux Therapeutics](https://aibio.space/companies/janux-therapeutics/) NASDAQ: JANX - [Equillium](https://aibio.space/companies/equillium/) NASDAQ: EQ - [City Therapeutics](https://aibio.space/companies/city-therapeutics/) NASDAQ: CTY - [Verastem](https://aibio.space/companies/verastem/) NASDAQ: VSTM - [AnaptysBio](https://aibio.space/companies/anaptysbio/) NASDAQ: ANAB - [Coya Therapeutics](https://aibio.space/companies/coya-therapeutics/) NASDAQ: COYA - [BioAge Labs](https://aibio.space/companies/bioage-labs/) NASDAQ: BIOA - [Neurogene](https://aibio.space/companies/neurogene/) NASDAQ: NGNE ### Also on NASDAQ - [CYPHERPUNK TECHNOLOGIES INC.](https://aibio.space/companies/cypherpunk-technologies/) CYPH - [SCYNEXIS](https://aibio.space/companies/scynexis/) SCYX - [Nexalin Technology](https://aibio.space/companies/nexalin-technology/) NXL - [XORTX Therapeutics](https://aibio.space/companies/xortx-therapeutics/) XRTX - [BioCryst Pharmaceuticals](https://aibio.space/companies/biocryst-pharmaceuticals/) BCRX - [Aytu BioPharma](https://aibio.space/companies/aytu-biopharma/) AYTU ## What Cadrenal Therapeutics does Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its lead product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed for heparin-induced thrombocytopenia, an immune-mediated thrombotic disorder. The company acquired CAD-1005 and the CAD-2000 series from Veralox Therapeutics Inc. on December 10, 2025. It completed an End-of-Phase 2 meeting with the FDA on March 26, 2026, which clarified a potential registrational path for a planned Phase 3 pivotal trial, subject to the final FDA meeting minutes and protocol review. CAD-1005 holds an orphan drug designation and FDA Fast Track designation for heparin-induced thrombocytopenia. The broader pipeline includes tecarfarin, an oral vitamin K antagonist designed for chronic use in patients with kidney dysfunction or left ventricular assist devices, and frunexian, a Phase 2-ready intravenous Factor XIa inhibitor for acute care settings. Commencement of the Phase 3 trial will be subject to obtaining sufficient financing. | Product or program | What it is | Stage | |---|---|---| | CAD-1005 | First-in-class selective 12-LOX inhibitor for heparin-induced thrombocytopenia | Phase 2 completed; planned Phase 3 pivotal trial | | Tecarfarin | Oral vitamin K antagonist for chronic anticoagulation in patients with kidney dysfunction or LVADs | clinical-stage | | Frunexian | Intravenous Factor XIa inhibitor for acute care hospital settings | Phase 2-ready | Summarised from the company's [10-K filed Mar 31, 2026](https://www.sec.gov/Archives/edgar/data/1937993/000121390026036946/ea0283741-10k_cadrenal.htm). ## Cadrenal Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$4.1 million](https://www.sec.gov/Archives/edgar/data/1937993/000121390026036946/) | [$4.2 million](https://www.sec.gov/Archives/edgar/data/1937993/000121390026036946/) | | Net income (loss) | [-$13.2 million](https://www.sec.gov/Archives/edgar/data/1937993/000121390026036946/) | [-$10.7 million](https://www.sec.gov/Archives/edgar/data/1937993/000121390026036946/) | | Cash from operations | [-$12.6 million](https://www.sec.gov/Archives/edgar/data/1937993/000121390026036946/) | [-$7.4 million](https://www.sec.gov/Archives/edgar/data/1937993/000121390026036946/) | | Cash and equivalents | [$4.0 million](https://www.sec.gov/Archives/edgar/data/1937993/000121390026089153/) | [$10.0 million](https://www.sec.gov/Archives/edgar/data/1937993/000121390026036946/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $2.4 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Cadrenal Therapeutics Has Cadrenal Therapeutics raised money recently? Our latest story on this, dated Jul 1, 2026: "Cadrenal Therapeutics raises $3.0 million in private placement priced at-the-market". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/cadrenal-therapeutics-raises-3-0-million-private-placement-priced/). What is the ticker symbol of Cadrenal Therapeutics? Cadrenal Therapeutics, Inc. trades under the ticker CVKD on NASDAQ. Where is Cadrenal Therapeutics listed? Cadrenal Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Cadrenal Therapeutics? The SEC Central Index Key (CIK) for Cadrenal Therapeutics, Inc. is 1937993. Its filings are on SEC EDGAR. How many shares does Cadrenal Therapeutics have outstanding? 3,567,592 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Cadrenal Therapeutics listed under? Our directory records Cadrenal Therapeutics, Inc. under United States. What does Cadrenal Therapeutics do? Our directory classifies Cadrenal Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Cadrenal Therapeutics? The ISIN recorded for Cadrenal Therapeutics, Inc. is US1276362076. Does aibio.space cover Cadrenal Therapeutics? aibio.space lists Cadrenal Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Cadrenal Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Cadrenal Therapeutics develop? Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its lead product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed for heparin-induced thrombocytopenia, an immune-mediated thrombotic disorder. What is CAD-1005 from Cadrenal Therapeutics? CAD-1005: First-in-class selective 12-LOX inhibitor for heparin-induced thrombocytopenia Stage: Phase 2 completed; planned Phase 3 pivotal trial. What is Tecarfarin from Cadrenal Therapeutics? Tecarfarin: Oral vitamin K antagonist for chronic anticoagulation in patients with kidney dysfunction or LVADs Stage: clinical-stage. Is Cadrenal Therapeutics profitable? Cadrenal Therapeutics, Inc. reported a net loss of $13.2 million for the fiscal year ended Dec 31, 2025, and used $12.6 million of cash in operations, per its annual report to the SEC. How much does Cadrenal Therapeutics spend on research and development? $4.1 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Cadrenal Therapeutics Members talk about Cadrenal Therapeutics (CVKD). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Cadrenal Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-07-01 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1937993/000121390026074421/ea029666601ex99-1.htm) 2. 2025-12-16 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1937993/000121390025121928/ea0269736-424b5_cadrenal.htm) 3. 2025-11-18 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1937993/000121390025112118/ea0266063-424b5_cadrenal.htm) 4. 2025-11-10 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1937993/000121390025107816/ea0263343-10q_cadrenal.htm) 5. 2025-04-17 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1937993/000121390025032730/ea0238493-424b5_cadrenal.htm) 6. 2024-12-20 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1937993/000121390024111291/ea0225406-424b5_cadrenal.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:CVKD on TradingView](https://www.tradingview.com/symbols/NASDAQ-CVKD/). ## SEC filings and registration - **SEC name**: Cadrenal Therapeutics, Inc. - **CIK**: 1937993 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: CVKD (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 822 A1A NORTH, PONTE VEDRA, FL, 32082 - **Phone**: 904-300-0701 - **Shares outstanding**: 3,567,592 as of 2026-08-13 (10-Q filed 2026-08-13) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1937993/000121390026107442/ea0307947-8k_cadrenal.htm) filed 2026-10-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1937993/000121390026104647/ea0306613-8k_cadrenal.htm) filed 2026-09-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1937993/000121390026095394/ea0303997-8k_cadrenal.htm) filed 2026-08-31 - [10-Q](https://www.sec.gov/Archives/edgar/data/1937993/000121390026089153/ea0301223-10q_cadrenal.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1937993/000121390026089147/ea0302042-8k_cadrenal.htm) filed 2026-08-13 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1937993/000121390026084710/ea0298910-02.htm) filed 2026-08-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1937993/000121390026079824/ea0298669-8k_cadrenal.htm) filed 2026-07-21 - [8-K](https://www.sec.gov/Archives/edgar/data/1937993/000121390026079176/ea0298082-8k_cadrenal.htm) filed 2026-07-17 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001937993), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Cadrenal Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CVKD, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Cadrenal Therapeutics, Inc. - **Ticker**: CVKD - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US1276362076 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-CVKD/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/cadrenal-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Cadrenal Therapeutics (CVKD) news: offering", 2026-10-31, https://aibio.space/companies/cadrenal-therapeutics/